Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching type 2 diabetes may encounter umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy as an adjunctive treatment approach. In China, this therapy is available through the Boao Lecheng International Medical Tourism Pilot Zone's pilot-and-trial access policy. This guide explains what the treatment is, who may be considered, its estimated cost, where it is offered, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is Umbilical Cord-Derived Mesenchymal Stem Cell Therapy?
Type 2 diabetes stem cell therapy in China may include umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy, which uses mesenchymal stem cells obtained from umbilical cord tissue. The cells are administered intravenously as an adjunctive therapy rather than as a standalone treatment for the insulin resistance and beta-cell dysfunction associated with type 2 diabetes.
The proposed mechanism of type 2 diabetes stem cell therapy in China focuses on modifying the surrounding biological environment through immune regulation, anti-inflammatory effects, and the secretion of signaling factors through paracrine activity. The treatment is not intended to replace hypoglycemic medication.
This UC-MSC approach is distinct from another type 2 diabetes treatment listing involving GLP-1/FGF21 dual-factor adipose stem cells. The two approaches use different cell sources and are described with different mechanisms, although both target type 2 diabetes.
Is Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Available in China?
Yes, through a specific medical-access pathway in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. The therapy is included in the zone's official conversion application directory under its pilot-and-trial access policy.
The regulatory classification is described as low risk, with registration in 2025 and approval number [2025] No. 113 of the State Administration of Traditional Chinese Medicine.
Pilot-zone access does not mean that the therapy has nationwide approval for routine use throughout China. Access remains subject to the applicable pilot-zone procedures and medical assessment.
Where Is the Treatment Offered for Type 2 Diabetes Stem Cell Therapy China?
The treatment is offered at Le Cheng Hospital (Ciming Boao International Hospital), First Affiliated Hospital of Hainan Medical University in the Boao Lecheng International Medical Tourism Pilot Zone.
Technical support is provided by Shenzhen Beike Biotechnology Co., Ltd. The cell type used is umbilical cord-derived mesenchymal stem cells from perinatal tissue.
Who May Be Eligible?
Eligibility is focused on type 2 diabetes patients who have not achieved adequate blood sugar control despite combining at least three antidiabetic medications, including insulin.
Suitability is evaluated by the attending physician during an in-person consultation and examination. Patients cannot determine their own eligibility based solely on these criteria.
Final eligibility is determined by the treating medical team after a face-to-face consultation and examination.
How Much Does It Cost?
The estimated cost is ¥58,000 (approximately US$8,600) per injection, with three injections per treatment course, based on an exchange rate of about ¥6.74 per US dollar. That makes the treatment-course estimate approximately ¥174,000 (US$25,800) for three injections.
The stated price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, medication, or travel. Confirm the final pricing and exactly what is included directly with the hospital before making travel arrangements.
Why International Patients May Consider This Option
For some international patients with type 2 diabetes that remains inadequately controlled despite multiple medications, a supervised access pathway for an adjunctive cell-based treatment may be worth discussing with qualified specialists.
The Lecheng pathway provides a defined hospital-based route to explore this treatment in China. However, its availability through a pilot-zone policy should not be interpreted as proof that it is more effective than established diabetes management or as evidence of a cure. Patients should discuss the potential benefits, risks, evidence, alternatives, and continued need for standard diabetes treatment with their physicians.
How ChinaCureLink Can Help International Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and type 2 diabetes-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Le Cheng Hospital (Ciming Boao International Hospital), First Affiliated Hospital of Hainan Medical University in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is UC-MSC therapy for type 2 diabetes available in China?
Yes. It is available through the Boao Lecheng International Medical Tourism Pilot Zone's pilot-and-trial access pathway at Le Cheng Hospital in Hainan. This does not constitute nationwide approval.
How much does UC-MSC therapy for type 2 diabetes cost in China?
The estimated cost is approximately US$8,600 per injection, with three injections per treatment course, for an estimated treatment-course cost of approximately US$25,800 (¥174,000). Final pricing should be confirmed with the hospital.
Who may qualify for UC-MSC therapy for type 2 diabetes?
The eligibility criterion is type 2 diabetes with inadequate blood sugar control despite at least three antidiabetic medications, including insulin. Final suitability requires physician assessment.
Does UC-MSC therapy replace diabetes medication?
No. The treatment is positioned as an adjunctive therapy and is not intended to replace hypoglycemic medications or standard diabetes management.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
